The Sorafenib for Hepatocellular Carcinoma (HCC) in Adjuvant Setting: The End of the Story was Already Written?

Mohamed Bouattour
  • Gastroenterology & Hepatology Open Access, August 2014, MedCrave Group LLC
  • DOI: 10.15406/ghoa.2014.01.00015
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Mohamed Bouattour